采血笔市场 - 全球产业规模、份额、趋势、机会、预测：按类型、应用、最终用户、地区和竞争格局划分，2021-2031年

全球采血针市场预计将从 2025 年的 26.8 亿美元大幅成长至 2031 年的 47.3 亿美元，复合年增长率为 9.95%。

采血针是一种无菌、一次性医疗器械，其尖端锋利，用于毛细血管采血，是血糖监测和各种诊断任务的必备工具。推动其市场成长的主要因素是需要定期验血的慢性病盛行率不断上升，以及患者自我监测需求的日益增长。全球人口老化和严格的感染控制通讯协定（要求使用一次性安全器械）进一步加剧了这一成长趋势。根据国际糖尿病联盟的数据，到2024年，全球将有约5.89亿成年人患有糖尿病，将对常规监测用品产生持续且庞大的需求。

儘管成长前景强劲，但挑战依然存在，主要源自于频繁的皮肤穿刺带来的疼痛和不适。这些都会对患者的依从性产生负面影响，并削弱疾病管理的有效性。此外，糖尿病管理产品报销政策不完善，限制了发展中地区患者获得这些重要工具的机会，从而阻碍了市场进一步扩张。

市场驱动因素

全球采血针市场的主要驱动力是糖尿病和其他慢性疾病在全球范围内的日益普及。有效控制血糖需要频繁进行毛细血管采血。这一普遍存在的健康挑战导致对无菌采血针针的需求持续增长，尤其是在家庭自我管理疗法中，这对于预防长期併发症至关重要。美国疾病管制与预防中心 (CDC) 于 2024 年 5 月发布的《国家糖尿病统计报告》凸显了这项需求的规模。报告指出，美国有 3,840 万名糖尿病患者，这意味着庞大的人口依赖日常诊断耗材。因此，医疗保健系统正在大力投资管理用品，国际糖尿病联盟 (IDF) 估计，到 2024 年，全球与糖尿病相关的医疗保健支出将达到 1 兆美元，这凸显了采血针等护理产品的巨大经济影响。

同时，由于旨在预防事故的安全采血针的广泛应用，市场格局正在重塑。这一趋势的驱动力在于严格的监管要求以及临床环境中对职业安全日益增长的关注。医疗机构正在逐步淘汰标准设备，转而使用带有存储机制的安全采血针，以最大限度地降低意外刺伤和病原体传播的风险。鑑于感染疾病的普遍存在，这种转变至关重要，因为在诊断过程中必须确保操作安全。正如世界卫生组织（世卫组织）于2024年4月发布的《2024年全球肝炎报告》所指出的，全球约有2.54亿人患有慢性乙型肝炎，凸显了使用安全设计工具以确保医护人员在血液筛检测试中安全的重要性。

市场挑战

全球采血针市场成长的主要障碍在于发展中地区缺乏完善的报销政策和有限的取得途径。儘管定期血糖监测的临床需求毋庸置疑，但在公共医疗保险不足的低收入地区，这些必需耗材的费用往往由患者自行承担。这种经济压力迫使许多用户节约使用耗材，导致一次性采血采血针的重复使用（存在安全隐患）以及检测频率降低。这些行为直接减少了销售量对于市场收入至关重要。

糖尿病治疗成本的飙升反映了这项经济挑战的严峻性，给医疗保健预算带来了沉重负担，并限制了一次性诊断设备的资金投入。根据国际糖尿病联盟（IDF）估计，到2024年，全球糖尿病医疗支出预计将达到1.015兆美元。如此巨大的财政负担迫使支付方和政府机构优先考虑急性治疗，并在资源匮乏的环境中推迟对监测设备的投资，从而阻碍了高成长地区的市场渗透。因此，资金筹措机制的差异已成为一个主要瓶颈，阻碍了市场充分利用新兴经济体日益增长的糖尿病盛行率。

市场趋势

全球采血针市场正经历着微针采血技术的显着成长，该技术消除了传统指尖采血带来的不适感。这些先进的设备采用细针排列，可无痛采集毛细血管血，直接降低患者的焦虑，并有助于提高患者对常规检查的依从性。这项技术进步在分散式临床试验和居家诊断中尤其重要，因为使用者体验对于准确收集数据至关重要。在2025年3月发布的商业性进展新闻稿中，Tasso确认其以患者为中心的采血设备销量已超过150万台，证实了市场对近乎无痛采样解决方案日益增长的需求。

同时，为了减少一次性诊断耗材对环境的影响，医疗产业正稳步转向使用永续和环保材料。製造商积极审查其生产流程，以减少塑胶废弃物，并将回收聚合物应用于设备机壳，同时保持严格的无菌性和性能标准。这项策略转变直接回应了监管机构和相关部门日益增长的需求，即减少日常一次性产品产生的巨量医疗废弃物。例如，Greiner AG于2025年5月发布的《2024年度永续发展报告》强调，该公司在2024年将其集团整体废弃物总量减少了17%，这表明整个产业正在努力将循环经济原则应用于製造供应链。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球采血设备市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 类型（安全采血针、标准采血针、特殊采血针）
  • 依应用领域（血糖测量、血红素测量、血液凝固检验及其他应用）
  • 按最终使用者（医院/诊所、居家医疗环境、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美采血设备市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲采血设备市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区采血设备市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲采血设备市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲采血设备市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球采血设备市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• F. Hoffmann-La Roche Ltd
• Ypsomed AG
• B. Braun SE
• Terumo Medical Corporation
• Owen Mumford Ltd
• HTL-STREFA SA（MTD Medical Technology and Devices SpA）
• ARKRAY, Inc
• Sarstedt AG & Co. KG
• Medline Industries, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Lancets Market is projected to expand significantly, rising from a valuation of USD 2.68 Billion in 2025 to USD 4.73 Billion by 2031, reflecting a CAGR of 9.95%. As sterile, single-use medical instruments equipped with sharp points for capillary blood sampling, lancets are indispensable for glucose monitoring and various diagnostic tasks. Growth is primarily propelled by the increasing incidence of chronic diseases that necessitate regular blood testing and the growing need for patients to perform self-monitoring. This upward trend is reinforced by an aging global demographic and stringent infection control protocols that dictate the use of disposable safety mechanisms. Data from the International Diabetes Federation indicates that approximately 589 million adults were living with diabetes globally in 2024, generating a consistent and substantial demand for daily monitoring supplies.

Despite this robust growth outlook, the market encounters obstacles stemming from the pain and discomfort caused by frequent skin punctures, which can negatively impact patient compliance and compromise disease management efficacy. Furthermore, the accessibility of these essential tools is restricted in developing regions due to insufficient reimbursement policies for diabetes management supplies, which ultimately limits the market's broader expansion.

Market Driver

The primary force driving the Global Lancets Market is the rising global prevalence of diabetes and other chronic conditions, which necessitates frequent capillary blood sampling to maintain effective glycemic control. This widespread health challenge creates an enduring demand for sterile lancing devices, especially for home-based self-monitoring regimens that are vital for averting long-term complications. The scale of this requirement is highlighted by the Centers for Disease Control and Prevention's 'National Diabetes Statistics Report' from May 2024, which identified 38.4 million individuals with diabetes in the United States, indicating a massive population dependent on daily diagnostic consumables. Consequently, healthcare systems are investing heavily in management supplies, with the International Diabetes Federation estimating global health expenditure on diabetes reached USD 1 trillion in 2024, underscoring the significant economic impact of care products like lancets.

Simultaneously, the market is being reshaped by the increasing adoption of safety lancets designed to prevent needlestick injuries, a trend driven by strict regulatory requirements and a heightened focus on occupational safety within clinical settings. Medical facilities are progressively replacing standard devices with engineered safety lancets featuring retractable mechanisms to minimize the risk of accidental punctures and pathogen transmission. This shift is essential given the prevalence of infectious diseases that demand secure handling during diagnostics. As noted in the World Health Organization's 'Global Hepatitis Report 2024' released in April 2024, roughly 254 million people globally were living with chronic hepatitis B, emphasizing the critical need for safety-engineered tools to safeguard healthcare workers during blood screening procedures.

Market Challenge

A significant hurdle impeding the growth of the global lancets market is the lack of adequate reimbursement policies and limited accessibility within developing regions. Although the clinical requirement for regular blood glucose monitoring is undeniable, the financial responsibility for these necessary supplies frequently falls on patients in lower-income groups where public health coverage is lacking. This economic pressure compels many users to ration their supplies, leading to the hazardous reuse of single-use lancets or a decrease in testing frequency, behaviors that directly reduce the volume of consumable sales essential for market revenue.

The severity of this economic challenge is reflected in the escalating costs of diabetes care, which exert tremendous strain on healthcare budgets and restrict funding for disposable diagnostics. The International Diabetes Federation reported that diabetes accounted for an estimated USD 1.015 trillion in global health expenditure in 2024. This massive financial burden forces payers and government entities in resource-limited settings to prioritize acute medications over monitoring devices, effectively hindering market penetration in regions with high growth potential. As a result, disparities in funding mechanisms create a major bottleneck, preventing the market from fully leveraging the increasing disease prevalence in emerging economies.

Market Trends

The Global Lancets Market is witnessing a distinct rise in microneedle-based blood collection technologies aimed at eliminating the discomfort linked to conventional fingersticks. These advanced devices employ microscopic arrays to obtain capillary blood without pain, directly mitigating patient anxiety and enhancing adherence to regular testing schedules. This technological evolution is particularly significant for decentralized clinical trials and home-based diagnostics, where user experience is critical for accurate data collection. In a press statement from March 2025 regarding its commercial advancements, Tasso, Inc. confirmed the sale of over 1.5 million of its patient-centric blood collection devices, confirming the growing market appetite for virtually pain-free sampling solutions.

In parallel, the industry is shifting robustly toward the use of sustainable and eco-friendly materials to reduce the environmental impact of single-use diagnostic consumables. Manufacturers are actively reworking production methods to decrease plastic waste and are integrating recycled polymers into device casings while maintaining strict sterility and performance standards. This strategic move is a direct response to increasing regulatory and institutional demands to cut down the substantial volume of medical waste resulting from daily disposable items. For instance, Greiner AG's 'Annual and Sustainability Report 2024', released in May 2025, highlighted that the company achieved a 17% reduction in its group-wide total waste volume in 2024, demonstrating a sector-wide dedication to applying circular economy principles within the manufacturing supply chain.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Ypsomed AG
• B. Braun SE
• Terumo Medical Corporation
• Owen Mumford Ltd
• HTL-STREFA S.A. (MTD Medical Technology and Devices S.p.A.)
• ARKRAY, Inc
• Sarstedt AG & Co. KG
• Medline Industries, Inc.

Report Scope

In this report, the Global Lancets Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lancets Market, By Type

• Safety Lancets
• Standard Lancets
• Specialty Lancets

Lancets Market, By Application

• Glucose Testing
• Haemoglobin Testing
• Coagulation Testing
• Other Applications

Lancets Market, By End User

• Hospitals and Clinics
• Home Care Settings
• Others

Lancets Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lancets Market.

Available Customizations:

Global Lancets Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lancets Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Safety Lancets, Standard Lancets, Specialty Lancets)
  • 5.2.2. By Application (Glucose Testing, Haemoglobin Testing, Coagulation Testing, Other Applications)
  • 5.2.3. By End User (Hospitals and Clinics, Home Care Settings, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Lancets Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lancets Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Lancets Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Lancets Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Lancets Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lancets Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Lancets Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Lancets Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Lancets Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Lancets Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Lancets Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lancets Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Lancets Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Lancets Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Lancets Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Lancets Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Lancets Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lancets Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Lancets Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Lancets Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Lancets Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lancets Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Lancets Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Lancets Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lancets Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Ypsomed AG
• 15.3. B. Braun SE
• 15.4. Terumo Medical Corporation
• 15.5. Owen Mumford Ltd
• 15.6. HTL-STREFA S.A. (MTD Medical Technology and Devices S.p.A.)
• 15.7. ARKRAY, Inc
• 15.8. Sarstedt AG & Co. KG
• 15.9. Medline Industries, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer